Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Melanoma 28Carcinoma, Non-Small-Cell Lung 28Neoplasm Metastasis 23Carcinoma, Hepatocellular 22Colorectal Neoplasms 19Triple Negative Breast Neoplasms 16Pancreatic Neoplasms 15Neoplasms 15Stomach Neoplasms 14Squamous Cell Carcinoma of Head and Neck 13Nasopharyngeal Carcinoma 13Carcinoma, Renal Cell 13Uterine Cervical Neoplasms 10Rectal Neoplasms 10Lymphoma 8Sarcoma 7Esophageal Squamous Cell Carcinoma 7Esophageal Neoplasms 7Recurrence 6Lymphoma, Extranodal NK-T-Cell 6Lung Neoplasms 6Locally Advanced Rectal Cancer 6Breast Neoplasms 6Advanced Solid Tumor 6Ovarian Neoplasms 5Liver Neoplasms 5Glioblastoma 5Endometrial Neoplasms 5Cholangiocarcinoma 5Small Cell Lung Carcinoma 4

Interventions

Magnetic Resonance Spectroscopy 10Iodine-131 8selpercatinib 5Thyrotropin Alfa 5trametinib 4dabrafenib 4Vemurafenib 4Thyroidectomy 4lenvatinib 3cabozantinib 3Transurethral Resection of Prostate 3Sunitinib 3Specimen Handling 3Sorafenib 3Radiofrequency Ablation 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3vandetanib 2entrectinib 2cobimetinib 2X-Rays 2Trastuzumab 2Thyroid (USP) 2Surgical Procedures, Operative 2Rosiglitazone 2Radiotherapy 2Nivolumab 2Lymph Node Excision 2Interviews as Topic 2Gefitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Cancer, Papillary × spartalizumab × Clear all
NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
19 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡